Sanofi (+3.11% €93.10)
After two sessions of withdrawal, Sanofi offered a rebound. The group benefited from a favorable rating from Oddo BHF (price target raised to 111 euros and Outperformance opinion maintained, according to a market source) and the approval by the Food and Drug Administration (FDA) of Enjaymo (sutimlimab -jome) to reduce the need for red blood cell transfusions to treat hemolysis in adults with cold agglutinin disease (CAD).